|
|
|
|
Gene profiling of patients with chronic fatigue syndrome/myalgic encephalomyelitis - Source: Curren
Chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME) is a multisystem disease, the pathogenesis of which remains undetermined.Following two microarray studies, we reported the differential expression of 88 human genes in patients...
|
|
|
Immunologic, clinical, and radiologic status 14 months after cessation of natalizumab therapy
Stuve O et al.- This is the first long-term follow-up of patients who discontinued natalizumab. We did not observe a clinical, radiographic, or immunologic rebound phenomenon after discontinuation of natalizumab therapy. ...
|
|
|
Immunologic changes in children with egg allergy ingesting extensively heated egg
Lemon-Mule H et al.- The majority of subjects with egg allergy were tolerant of heated egg. Continued ingestion of heated egg was well tolerated and associated with immunologic changes that paralleled the changes observed with the...
|
|
|
TopAbstracts in AIDS and HIV 11/10/2008
TopAbstracts in AIDS and HIV are the abstracts most highly rated/most read by nearly 300,000 physicians who received a Doctor's Guide newsletter or visited a website Powered by Doctor's Guide in the past 14 days.Over 2000 peer-reviewed...
|
|
|
Immunologic and clinical status 14 months after cessation of natalizumab therapy
Stuve O et al.- This is the first long-term follow-up of patients who discontinued natalizumab. We did not observe a clinical, radiographic, or immunologic rebound phenomenon after discontinuation of natalizumab therapy. --- NEURO...
|
|
|
A Comparison of Clinical and Immunologic Features in Children and Older Patients Hospitalized With Severe Chol
Chowdhury F et al.- Although children developed vigorous vibriocidal and CTB-specific responses following infection, they had lessened responses to LPS and TcpA compared with older patients, as well as lessened responses to vaccination.
|
|
|
96-Week Data From CASTLE Study Continue to Show Similar Efficacy Between Once-Daily REYATAZ(R) (atazanavir sul
PRINCETON, N.J.-(Business Wire)-October 26, 2008 - Bristol-Myers Squibb Company (NYSE: BMY) today announced 96-week data from the CASTLE study, in which 74 percent of the 440 patients in the REYATAZ (atazanavir sulfate)/r arm achieved an...
|
|
|
96-Week Data From CASTLE Study Continue to Show Similar Efficacy Between Once-Daily REYATAZ(R) (atazanavir sul
Data continue to show differences in gastrointestinal and lipid effects among study population PRINCETON, N.J.--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY - News) today announced 96-week data from the CASTLE study, in which 74...
|
|
|
96-Week Data From CASTLE Study Continue to Show Similar Efficacy Between Once-Daily REYATAZ(R) (atazanavir sul
2008-10-2612:30ET - News Release Data continue to show differences in gastrointestinal and lipid effects among study population PRINCETON, N.J.-- (Business Wire) Bristol-Myers Squibb Company (NYSE: BMY) today announced 96-week data from...
|
|
|
Alba Therapeutics Presents New Data for Larazotide Acetate at the 2008 American College of Gastroenterology An
Study Showed Larazotide Acetate Prevented Immunologic Changes Induced by Gluten in Patients with Celiac Disease Additional Data Indicates Potential in Treating Inflammatory Bowel Disease ORLANDO, Fla., Oct.7 /PRNewswire/ -- Alba...
|
